Phathom Stock Skyrockets 124% on FDA Approval!

Phathom Pharmaceuticals, Inc. surged 124.41% in intraday trading, following the announcement of a positive FDA decision. The company, which focuses on developing novel treatments for gastrointestinal diseases, has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) marketed in the United States as VOQUEZNA® for various gastrointestinal conditions.